Search Results

You are looking at 111 - 120 of 2,671 items for :

  • Refine by Access: All x
Clear All
Full access

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

lack of lymph node sampling. AREN0532 demonstrated an excellent outcome with a high salvage rate for patients with disease relapse using a standardized regimen (DD4A; doxorubicin/vincristine/dactinomycin) and radiation therapy (RT) ( Table 2 ). 8 A

Full access

Praveen Adusumilli, Vidya Viswanath, and Raghunadha Rao Digumarthi

Introduction: Perception of pain and the need to treat it is highly variable, even amongst oncologists. Availability of pain specialists is an added advantage. This is an analysis of prescription patterns of pain medication and its outcome in

Full access

Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III

focused on receipt of locoregional treatment, compared with others with N0M0 disease, node-positive disease, or metastatic disease. We also studied survival outcomes among these various subgroups of patients and explored the possible survival benefit

Full access

Carlos H. Barcenas, Maryam N. Shafaee, Arup K. Sinha, Akshara Raghavendra, Babita Saigal, Rashmi K. Murthy, Ashley H. Woodson, and Banu Arun

primary outcome of interest was documentation of a formal recommendation from the medical provider for a genetic counseling session. Using the prospectively maintained Breast Cancer Database Management System housed in the Department of Breast Medical

Full access

Sapho X. Roodbeen, Marta Penna, Susan van Dieren, Brendan Moran, Paris Tekkis, Pieter J. Tanis, Roel Hompes, and on behalf of the International TaTME Registry Collaborative

surgeon’s ability to achieve a meticulous cancer dissection. This may impair oncologic outcomes, particularly for locally advanced lower rectal cancer in male patients. 2 – 4 A laparoscopic rectal cancer operation results in short-term patient benefits

Full access

Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin

pathologic complete response (pCR). 11 HER2 expression was found in 27% of resected locally advanced rectal adenocarcinomas and may be associated with improved outcomes after multimodality therapy. 12 A key potential resistance mechanism in colorectal

Full access

Jill R. Tichy, Elgene Lim, and Carey K. Anders

-related survival over the past 2 decades. 2 Several factors may explain the poor outcomes observed in this population, which may include a limited understanding of the biology of these cancers, inadequate clinical trial representation, and unique psychosocial and

Full access

Jason D. Goldman, Amelia Gallaher, Rupali Jain, Zach Stednick, Manoj Menon, Michael J. Boeckh, Paul S. Pottinger, Stephen M. Schwartz, and Corey Casper

measure relative risk of (1) cumulative 30-day mortality, (2) development of SSh, or (3) the combined outcome of cumulative 30-day mortality or development of SSh. Multivariate models were constructed to control for prespecified confounding variables

Full access

Maral DerSarkissian, Shuanglian Li, Aaron Galaznik, Rachel Bhak, Iryna Bocharova, Thomas Kulalert, Huamao M. Lin, Hui Huang, and Mei Sheng Duh

experience of NSCLC patients with EGFR exon 20 insertion mutations are limited. This study describes patient characteristics, treatment patterns, and survival outcomes of NSCLC patients with EGFR exon 20 insertions based on real world data. Methods

Full access

Mark L. Gonzalgo and H. Ballentine Carter

The use of prostate-specific antigen (PSA) testing for prostate cancer screening has increased dramatically over the past decade. Determining the most efficient way to use PSA testing and how to interpret total PSA levels and changes in PSA values over time remain challenging. Guidelines for early detection of prostate cancer have a direct impact on the number of unnecessary tests performed and are critical for developing a successful screening approach for prostate cancer. The age at which PSA screening should begin, PSA testing intervals, and the importance of understanding fluctuations in PSA values over time are discussed in the framework of recent discoveries in the field. Results from ongoing randomized trials will confirm whether prostate cancer screening is an effective method for reducing deaths from prostate cancer and what approaches will provide the most cost-effective screening strategies.